Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NJA-730 in Healthy Volunteers

Next Previous
Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NJA-730 in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs NJA 730 (Primary)
  • Indications Autoimmune disorders; Graft-versus-host disease
  • Focus Adverse reactions; First in man
  • Sponsors NapaJen Pharma

    • Most Recent Events

    • 15 Nov 2018 According to NapaJen Pharma media release, the company expects to report preliminary results from the study during the first half of 2019.
    • 15 Nov 2018 According to NapaJen Pharma media release, Status changed from not yet recruiting to recruiting.
    • 15 Nov 2018 According to NapaJen Pharma media release, first patient has been dosed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top